Enrollment Closed
1

Phase 2 Study for C3G and MPGN patients

A Proof of Concept Study for a 12 Month Treatment in Patients With C3 Glomerulopathy (C3G) or Immune-Complex Membranoproliferative Glomerulonephritis (IC-MPGN)

Brief Description

This study will determine the effectiveness of a compound called ACH-0144471 at improving the clinical symptoms of C3G of IC-MPGN

Trial Physician / Study Coordinator

Clinical Trial Team

Email Phone 203-752-5566
Site Name

Yale University School of Medicine

Sponsor

Achillion Pharmaceuticals

Study Drug

ACH-0144471

Estimated enrollment

20

Estimated end date

May, 2020

If there is not a site for a clinical trial nearby, you can ask the study team about the possibility of travel reimbursements (i.e., paying you back for your travel costs). Alternatively, you can ask about the possibility of participating from home.
Find other locations for this trial:
Enrollment Closed
1

Phase 2 Study for C3G and MPGN patients

A Proof of Concept Study for a 12 Month Treatment in Patients With C3 Glomerulopathy (C3G) or Immune-Complex Membranoproliferative Glomerulonephritis (IC-MPGN)

Brief Description

This study will determine the effectiveness of a compound called ACH-0144471 at improving the clinical symptoms of C3G of IC-MPGN

Trial is for people with

C3 Glomerulonephritis / C3 Glomerulopathy (C3G) or Immune Complex Membranoproliferative Glomerulonephritis
(IC-MPGN)

Study Goal

This study will look at the whether the study drug is improving symptoms through a renal biopsy.

What is involved for the Patient?

Patients will participate for 1 year. Additional study visits and diagnostic tests may be required, including biopsies and labwork.

About the drug or intervention

ACH-0144471 is an oral tablet that study participants will take daily.

Find other locations for this trial:
New Haven, CT
Frequently Asked Questions

Nephrotic Syndrome is not a disease itself, but rather a group of signs and symptoms that result from damage in the part of the kidney that filters blood (glomeruli).

Common symptoms include:

  • Foamy urine (called proteinuria) caused by protein “spilling” into the urine
  • Severe swelling in parts of the body, most noticeably around the eyes, hands, feet, and abdomen (called edema)
  • Weight gain due to a buildup of extra fluid
  • Fatigue
  • Loss of appetite
  • Low levels of protein in the blood (hypoalbuminemia)
  • Higher than normal fat and cholesterol levels in the blood (hyperlipidemia)

Nephrotic Syndrome can typically be diagnosed with a urine test.

Nephrotic Syndrome can be “primary” or “secondary” in nature.

Diseases that affect only the kidneys are called primary causes of Nephrotic Syndrome. Doctors often call these diseases “idiopathic,” which means that they arise from an unknown cause. Some of these diseases include:

  • Minimal Change Disease (MCD) – most common in children
  • Focal Segmental Glomerulosclerosis (FSGS)
  • Membranous Nephropathy (MN) – most common in adults
  • IgA Nephropathy (IgAN)

Secondary Nephrotic Syndrome is caused by an underlying, systemic condition like diabetes, lupus, HIV, and others.

The Kidney Health Gateway is a website owned and operated by NephCure Kidney International. The purpose of this website is to help patients with rare forms of primary Nephrotic Syndrome get connected to expert care and cutting-edge treatment options. By answering a few questions about you or your loved one’s condition, we can provide you with a list of clinical trials and/or expert doctors in your area.

If you have additional questions, please visit NephCure.org or email Info@NephCure.org.

 

See other frequently asked questions